Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19. 

Although not official and largely anecdotal, there are early signs that Gilead Sciences’ experimental antiviral drug remdesivir is effective in treating COVID-19.

Gilead Sciences is running at least five clinical trials for the company’s experimental antiviral drug remdesivir against COVID-19.

Regeneron Pharmaceuticals Inc. is ramping up efforts to develop a set of coronavirus treatments, which could be available for testing or use in some patients within a few months, the drugmaker said on Thursday.

Catalyst Pharmaceuticals Inc., under fire for a high price tag on a rare disease drug, sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival medicine.

The FDA said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds.